| Literature DB >> 20535131 |
Timothy A Yap1, Shahneen K Sandhu, Paul Workman, Johann S de Bono.
Abstract
The development of novel molecularly targeted cancer therapeutics remains slow and expensive with many late-stage failures. There is an urgent need to accelerate this process by improving early clinical anticancer drug evaluation through modern and rational trial designs that incorporate predictive, pharmacokinetic, pharmacodynamic, pharmacogenomic and intermediate end-point biomarkers. In this article, we discuss current approaches and propose strategies that will potentially maximize benefit to patients and expedite the regulatory approvals of new anticancer drugs.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20535131 DOI： 10.1038/nrc2870
Source DB: PubMed Journal: Nat Rev Cancer ISSN： 1474-175X Impact factor: 60.716